What non-behavioural therapies are being researched for autism?
A growing range of non-behavioural therapies are being explored as alternatives or complements to behavioural programmes. Current UK guidance, including NICE CG170 for under-19s and NICE CG142 for adults, emphasises psychosocial, communication-focused and functional skills support rather than “curing” autism. Research is now expanding into therapies that improve wellbeing, communication, and participation without aiming to change autistic identity or core traits.
NICE continues to advise against biomedical or experimental treatments such as secretin, chelation, hyperbaric oxygen or exclusion diets for core autism features. It’s 2021 surveillance review found that emerging therapies including sensory-integration trials, parent-mediated programmes, pharmacological pilots and developmental models were “unlikely to change guideline recommendations” at this stage.
Social-communication and psychological approaches
Parent-mediated social-communication interventions, such as the PACT programme, are among the most studied non-behavioural therapies. Evidence from trials such as this study shows improvements in parent–child interaction and some reductions in parent-reported autism symptoms. NICE treats these as psychosocial interventions rather than behavioural programmes, and they remain an important research focus.
For autistic adults, NICE recommends autism-adapted psychological therapies for co-existing mental health problems. Reviews such as this adaptation paper describe how CBT, mindfulness-based and acceptance-based approaches are being modified to suit autistic communication and processing styles. These do not aim to treat autism itself but support anxiety, depression, and OCD.
Pharmacological research
Several medications are being studied, but none are recommended for core autism features. Trials of bumetanide have shown early improvements in some rating scales, summarised in a 2021 systematic review, but NICE states evidence remains insufficient for clinical use. Other agents, including oxytocin, vasopressin antagonists, arbaclofen and gaboxadol show mixed results and continue to be classed as experimental, as summarised in a 2024 narrative review.
Sensory-informed and occupational approaches
UK occupational therapy guidance, such as the Lancashire & South Cumbria ICS Sensory Processing Position Statement, highlights occupation-focused sensory support to improve participation rather than aiming to “normalise” sensory responses. Ayres Sensory Integration is widely used but still has mixed evidence of quality, and recommendations emphasise careful goal setting, trained practitioners and integration within wider OT support.
Digital and assistive technologies
Emerging research also explores digital therapies and assistive communication tools. NHS AAC and electronic assistive technology services such as East Midlands AAC Service and the UHDB Electronic Assistive Technology Service support communication and independence using high-tech tools rather than behavioural modification. Government investment has expanded, with UKRI/NIHR assistive technology research funding apps, smart-technology wellbeing tools, and digital inclusion.
Takeaway
Non-behavioural therapies being researched for autism range from social-communication interventions and adapted psychological therapies to sensory-informed OT support, assistive technologies and experimental medications. NICE continues to prioritise psychosocial and functional approaches, emphasising safety, evidence quality and person-centred support. While many emerging therapies show promise, most remain in the research stage and are not yet recommended as routine treatment.
